AzurRx BioPharma Announces Reverse Merger With First Wave Bio

Benzinga

13 Sep 2021

AzurRx BioPharma Inc (NASDAQ: AZRX) has agreed to acquire First Wave Bio Inc in a stock and cash transaction valued at $229 million, including milestone payments.
First Wave Bio is a clinical-stage biotechnology company specializing in developing gut-targeted, small molecule therapies for autoimmune inflammatory bowel diseases (IBD).
In conjunction with the acquisition, AzurRx will change its name to First Wave BioPharma and trade on NASDAQ under the new ticker symbol, FWBI, effective by September 23.
In January, AzurRx in-licensed from First Wave Bio the exclusive global rights to develop two niclosamide therapeutic indications for COVID-19-related GI infections and immune checkpoint inhibitor-associated colitis and diarrhea (ICI-AC) in advanced-stage cancer patients.
Following the acquisition of First Wave Bio, AzurRx's internal development pipeline will include three new clinical IBD indications.
Last week, AzurRx BioPharma announced a reverse stock split of its common stock at a ratio of 1 post-split share for every 10 pre-split shares.
Also Read: Why AzurRx Stock Is Trading Higher After MS1819 Combo Therapy Data?
Price Action: AZRX shares are trading at $5.16 during the premarket session on the last check Monday.

See more from Benzinga

Click here for options trades from Benzinga
RedHill Biopharma To Test Its Oral Antiviral In COVID-19 Patients In South Africa
Why Are Leap Therapeutics Shares Trading Higher On Monday?

© 2021 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

1
2
3
4
5
6
7
8
9
10

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/news/2167873975"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2167873975\",edition:\"fundamental\",,,undefined,":{"share":"https://ttm.financial/m/news/2167873975?lang=en_US&edition=fundamental","thumbnail":"https://s.yimg.com/uu/api/res/1.2/ZRBBOa1tMJViMFVc8fXmEg--~B/aD00MDA7dz02MDA7YXBwaWQ9eXRhY2h5b24-/https://s.yimg.com/uu/api/res/1.2/0FNyfQ5yut_c43zYJ0mE8A--~B/aD00MDA7dz02MDA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/Benzinga/5320086803c22ca695d32783aaa0b7d3","is_english":true,"pubTime":"2021-09-13 21:19","share_image_url":"https://static.laohu8.com/5f26f4a48f9cb3e29be4d71d3ba8c038","id":"2167873975","market":"us","top_or_hot":-1,"title":"AzurRx BioPharma Announces Reverse Merger With First Wave Bio","media":"Benzinga","content":"<html><body><img height=\"400\" src=\"https://s1.yimg.com/uu/api/res/1.2/6BKrdrb.0YA.QwatkjOnfg--/cT03NTthcHBpZD15dmlkZW9mZWVkczs-/https://media.zenfs.com/en/Benzinga/5320086803c22ca695d32783aaa0b7d3\" title=\"\" width=\"600\"/>\n<ul>\n<li><strong>AzurRx BioPharma Inc</strong> (NASDAQ: AZRX) has agreed to acquire <strong>First Wave Bio Inc</strong> in a stock and cash transaction valued at $229 million, including milestone payments. </li>\n<li>First Wave Bio is a clinical-stage biotechnology company specializing in developing gut-targeted, small molecule therapies for autoimmune inflammatory bowel diseases (IBD).</li>\n<li>In conjunction with the acquisition, AzurRx will change its name to First Wave BioPharma and trade on NASDAQ under the new ticker symbol, FWBI, effective by September 23.</li>\n<li>In January, AzurRx in-licensed from First Wave Bio the exclusive global rights to develop two niclosamide therapeutic indications for COVID-19-related GI infections and immune checkpoint inhibitor-associated colitis and diarrhea (ICI-AC) in advanced-stage cancer patients. </li>\n<li>Following the acquisition of First Wave Bio, AzurRx's internal development pipeline will include three new clinical IBD indications.</li>\n<li>Last week, AzurRx BioPharma announced a reverse stock split of its common stock at a ratio of 1 post-split share for every 10 pre-split shares. </li>\n<li><strong><em>Also Read:</em></strong><em> </em><em>Why AzurRx Stock Is Trading Higher After MS1819 Combo Therapy Data?</em></li>\n<li><strong>Price Action:</strong> AZRX shares are trading at $5.16 during the premarket session on the last check Monday.</li>\n</ul>\n<p><strong>See more from Benzinga</strong></p>\n<ul>\n<li>Click here for options trades from Benzinga</li>\n<li>RedHill Biopharma To Test Its Oral Antiviral In COVID-19 Patients In South Africa</li>\n<li>Why Are Leap Therapeutics Shares Trading Higher On Monday?</li>\n</ul>\n<p><i>© 2021 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.</i></p></body></html>","source":"yahoofinance","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>AzurRx BioPharma Announces Reverse Merger With First Wave Bio</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nAzurRx BioPharma Announces Reverse Merger With First Wave Bio\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-09-13 21:19 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://finance.yahoo.com/news/azurrx-biopharma-announces-reverse-merger-131954264.html><strong>Benzinga</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>AzurRx BioPharma Inc (NASDAQ: AZRX) has agreed to acquire First Wave Bio Inc in a stock and cash transaction valued at $229 million, including milestone payments. \nFirst Wave Bio is a clinical-stage ...</p>\n\n<a href=\"https://finance.yahoo.com/news/azurrx-biopharma-announces-reverse-merger-131954264.html\">Source Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":null,"symbol_name":null,"start_time":0,"source_url":"https://finance.yahoo.com/news/azurrx-biopharma-announces-reverse-merger-131954264.html","article_id":"2167873975","we_media_id":null,"thumbnails":["https://s.yimg.com/uu/api/res/1.2/ZRBBOa1tMJViMFVc8fXmEg--~B/aD00MDA7dz02MDA7YXBwaWQ9eXRhY2h5b24-/https://s.yimg.com/uu/api/res/1.2/0FNyfQ5yut_c43zYJ0mE8A--~B/aD00MDA7dz02MDA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/Benzinga/5320086803c22ca695d32783aaa0b7d3"],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2167873975","pubTimestamp":1631539194,"columns":[],"sourceInfo":{"source_id":"yahoofinance","name":"雅虎金融"},"weMediaInfo":null,"summary":"AzurRx BioPharma Inc (NASDAQ: AZRX) has agreed to acquire First Wave Bio Inc in a stock and cash tra","collect":0,"end_time":0,"defaultTopTitle":"yahoo.com","property":[],"viewcount":null,"language":"en","relate_stocks":{},"translate_title":"AzurRx BioPharma宣布与First Wave Bio反向合并","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"AZRX":0.9},"content_text":"AzurRx BioPharma Inc (NASDAQ: AZRX) has agreed to acquire First Wave Bio Inc in a stock and cash transaction valued at $229 million, including milestone payments. \nFirst Wave Bio is a clinical-stage biotechnology company specializing in developing gut-targeted, small molecule therapies for autoimmune inflammatory bowel diseases (IBD).\nIn conjunction with the acquisition, AzurRx will change its name to First Wave BioPharma and trade on NASDAQ under the new ticker symbol, FWBI, effective by September 23.\nIn January, AzurRx in-licensed from First Wave Bio the exclusive global rights to develop two niclosamide therapeutic indications for COVID-19-related GI infections and immune checkpoint inhibitor-associated colitis and diarrhea (ICI-AC) in advanced-stage cancer patients. \nFollowing the acquisition of First Wave Bio, AzurRx's internal development pipeline will include three new clinical IBD indications.\nLast week, AzurRx BioPharma announced a reverse stock split of its common stock at a ratio of 1 post-split share for every 10 pre-split shares. \nAlso Read: Why AzurRx Stock Is Trading Higher After MS1819 Combo Therapy Data?\nPrice Action: AZRX shares are trading at $5.16 during the premarket session on the last check Monday.\n\nSee more from Benzinga\n\nClick here for options trades from Benzinga\nRedHill Biopharma To Test Its Oral Antiviral In COVID-19 Patients In South Africa\nWhy Are Leap Therapeutics Shares Trading Higher On Monday?\n\n© 2021 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"0","news_tag":"","news_rank":0,"symbols":[],"gpt_button":0,"code":"91000000","status":"200"}}}